Companies are frustratingly bad at keeping ClinicalTrials current and with important details. Sometimes shear ineptitude (RLMD only now updating, 9 months later), and sometimes malicious (TCDA had to work hard to conceal that they had changed protocol immensely from ph2 to ph3)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.